openPR Logo
Press release

Pancreatic Cancer Pipeline Review H1 2019

02-14-2019 07:55 AM CET | Health & Medicine

Press release from: ReportsWeb



Pancreatic Cancer - Pipeline Review, H1 2017

Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice) , loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Get Sample Copy at

Companies Mentioned:

3-V Biosciences Inc, 4P-Pharma SAS, AB Science SA, AbbVie Inc, AbGenomics International Inc, Ability Pharmaceuticals SL, Actuate Therapeutics Inc, Adamed Sp z oo, Aduro BioTech Inc, Advanced Cancer Therapeutics LLC, Advantagene Inc, Agenus Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alissa Pharma, Allinky Biopharma, Almac Discovery Ltd, Altor BioScience Corp, Ambrx Inc, amcure GmbH, American Gene Technologies International Inc, Amgen Inc, Anavex Life Sciences Corp, Andarix Pharmaceuticals Inc, ANP Technologies Inc, AntiCancer Inc, APEIRON Biologics AG, Aphios Corp, APIM Therapeutics AS, Apogenix GmbH, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc, Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, Autotelic Inc, AVEO Pharmaceuticals Inc, Axcentua Pharmaceuticals AB, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene (Beijing) Co Ltd, Bellicum Pharmaceuticals Inc, Berg LLC, BerGenBio ASA, Beta Pharma Inc, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, BioLineRx Ltd, Biomar Microbial Technologies, Biomunex Pharmaceuticals, Bioncotech Therapeutics SL, Bionomics Ltd, BioNTech AG, Biotest AG, Biouniversa srl, BLR Bio LLC, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd, Calithera Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Cantargia AB, Cascadian Therapeutics Inc, Cavion LLC, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Celleron Therapeutics Ltd, Cellular Biomedicine Group Inc, Celprogen Inc, Celyad SA, Centrose LLC, Ceronco Biosciences, ChemoCentryx Inc, Chugai Pharmaceutical Co Ltd, Clovis Oncology Inc, COARE Biotechnology Inc, Codiak BioSciences Inc, Concordia International Corp, Confluence Life Sciences Inc, Critical Outcome Technologies Inc, CrystalGenomics Inc, CTI BioPharma Corp, Cyclacel Pharmaceuticals Inc, CytomX Therapeutics Inc, Cytori Therapeutics Inc, CytRx Corp, CyTuVax BV, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, DEKK-TEC Inc, Denceptor Therapeutics Ltd, Diffusion Pharmaceuticals Inc, Eisai Co Ltd, Eleison Pharmaceuticals LLC, Eli Lilly and Company, Endor Nanotechnologies SL, Ensemble Therapeutics Corp, Ensol Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Etubics Corp, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faron Pharmaceuticals Oy, FibroGen Inc, Formosa Laboratories Inc, Forty Seven Inc, Fountain Biopharma Inc, Fujifilm Corp, Fusion Antibodies Ltd, Galena Biopharma Inc, GamaMabs Pharma SA, Geistlich Pharma AG, Genelux Corp, Genentech Inc, Genisphere LLC, Genmab A/S, Gilead Sciences Inc, GlaxoSmithKline Plc, Globeimmune Inc, GlycoMimetics Inc, Glycotope GmbH, Golden Biotechnology Corp, GW Pharmaceuticals Plc, Halozyme Therapeutics Inc, Helix BioPharma Corp, Horizon Pharma Plc, Humorigin Biotechnology Corp, iCeutica Inc, Idera Pharmaceuticals Inc, Igenica Biotherapeutics Inc, Ignyta Inc, Immodulon Therapeutics Ltd, Immune Pharmaceuticals Inc, Immune System Key Ltd, Immune Therapeutics Inc, Immunitor Inc, Immunomedics Inc, Immunotope Inc, Immunovo BV, Immupharma Plc, Incyte Corp, Inflection Biosciences Ltd, Innopharmax Inc, Innovation Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Intezyne Technologies Inc, Inventiva, InvivoGen Therapeutics, Io Therapeutics Inc, Ipsen SA, ISU ABXIS Co Ltd, Jasco Pharmaceuticals LLC, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kalyra Pharmaceuticals Inc, Kancera AB, Karcinolys SAS, Karyopharm Therapeutics Inc, Keystone Nano Inc, Komipharm International Co Ltd, Kura Oncology Inc, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Lidds AB, Lion Biotechnologies Inc, Lipopharma Therapeutics SL, Lixte Biotechnology Holdings Inc, Loxo Oncology Inc, Lymphocyte Activation Technologies SA, MabVax Therapeutics Holdings Inc, MacroGenics Inc, Mateon Therapeutics Inc, MaxiVAX SA, Meabco A/S, Mebiopharm Co Ltd, MediaPharma Srl, Medicenna Therapeutics Corp, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Millennium Pharmaceuticals Inc, Moleculin Biotech Inc, MolMed SpA, Monopar Therapeutics LLC, Morphotek Inc, Mount Tam Biotechnologies Inc, NanoCarrier Co Ltd, NantKwest Inc, Nascent Biotech Inc, Natco Pharma Ltd, NatureWise Biotech & Medicals Corp, NBE-Therapeutics AG, Nerviano Medical Sciences Srl, NewLink Genetics Corp, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, Novogen Ltd, Novus Therapeutics Inc, Noxxon Pharma AG, NuCana BioMed Ltd, OBI Pharma Inc, Omeros Corp, Oncodesign SA, Oncolytics Biotech Inc, Oncomatryx Biopharma SL, OncoMed Pharmaceuticals Inc, OncoTherapy Science Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Onxeo SA, Opsona Therapeutics Ltd, Optimum Therapeutics LLC, Orega Biotech SAS, Oribase Pharma, Oryx GmbH & Co KG, Patrys Ltd, Pfizer Inc, Pharma Two B Ltd, PharmAbcine Inc, PharmaCyte Biotech Inc, Pharmedartis GmbH, Phoenix Biotechnology Inc, Plexxikon Inc, Polaris Pharmaceuticals Inc, Precision Biologics Inc, Prima BioMed Ltd, Propanac Biopharma Inc, Provectus Biopharmaceuticals Inc, Puretech Health plc, Quest PharmaTech Inc, Quimatryx SL, Quintessence Biosciences Inc, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Redx Pharma Plc, Rexahn Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Samumed LLC, Samyang Holdings Corp, Sanofi, Sareum Holdings Plc, SATT North SAS, Selecta Biosciences Inc, Sierra Oncology Inc, SignPath Pharma Inc, Sillajen Biotherapeutics, Soricimed Biopharma Inc, Sorrento Therapeutics Inc, Spring Bank Pharmaceuticals Inc, Stelic Institute & Co Inc, Strongbridge Biopharma plc, Sumitomo Dainippon Pharma Co Ltd, Sun BioPharma Inc, Sun Pharma Advanced Research Company Ltd, Sunshine Biopharma Inc, Swedish Orphan Biovitrum AB, Symic Biomedical Inc , Symphogen A/S, SynCore Biotechnology Co Ltd, Synergys Biotherapeutics Inc, Synovo GmbH, SyntheX Inc, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takara Bio Inc, Takeda Pharmaceutical Company Ltd, Takis Srl, Targovax ASA, Tarveda Therapeutics Inc, tella Inc, Threshold Pharmaceuticals Inc, Tiltan Pharma Ltd, Tocagen Inc, Tolero Pharmaceuticals Inc, Transcriptogen Ltd, Transgene SA, TVAX Biomedical Inc, Tyg Oncology Ltd, Tyme Technologies Inc, Tyrogenex Inc, UbiVac LLC, ValiRx Plc, VasGene Therapeutics Inc, Vault Pharma Inc, Vaxeal Holding SA, Vaximm AG, Vaxon Biotech, VCN Biosciences SL, Vect-Horus SAS, Verastem Inc, VG Life Sciences Inc, Vicus Therapeutics LLC, ViiV Healthcare Ltd, Viralytics Ltd, Virobay Inc, ViroStatics srl, Wilex AG, Zeria Pharmaceutical Co Ltd

Make an Inquiry

Table of Contents:

Table of Contents 2
Introduction 13
Pancreatic Cancer - Overview 14
Pancreatic Cancer - Therapeutics Development 15
Pancreatic Cancer - Therapeutics Assessment 80
Pancreatic Cancer - Companies Involved in Therapeutics Development 117
Pancreatic Cancer - Drug Profiles 275
Pancreatic Cancer - Dormant Projects 1987
Pancreatic Cancer - Discontinued Products 2006
Pancreatic Cancer - Product Development Milestones 2011
Appendix 2027


- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology) .
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Contact Us:
Call: +1-646-491-9876
Email: is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.


This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pancreatic Cancer Pipeline Review H1 2019 here

News-ID: 1587232 • Views: 708

More Releases from ReportsWeb

Human Capital Management Solution Market Set for Rapid Growth during the Forecas …
Overview of Human Capital Management Solution Market Human capital administration (HCM) is a set of practices related to human resource administration. These practices are centered on the organizational have to be give particular competencies and are executed in three categories: workforce procurement, workforce administration and workforce optimization. Scope of the Report The research report titled ‘Human Capital Management Solution Market’ provides the newest industry data and industry future trends, allowing you to identify
Cable Cars and Ropeways Market to Witness a Pronounce Growth During 2025 – Top …
A Cable Car, Ropeways, aerial tramway, sky tram or aerial tram is defined as an aerial lift which uses one or two stationary supporting ropes for transporting vehicles, trolley, tram, lift, pallets etc. and third rope for providing propulsion. This form of lift maintains strong grip of fixed tramway with propulsion rope and cannot detach during operations. An electric motor is primarily deployed at the bottom of the tramway to
Brake Pad Market Outlook to 2025 | Airtex Vehicle Electronics, Automotive, BorgW …
Brake pads are used in automotive and other application and they are a component of brake disc. Brake pads are fixed in brake caliper and they helps in converting kinetic energy of vehicle into thermal energy. Increasing demand for environment friendly and light weight braking material is fueling the growth of brake pad. The major driving factor influencing the growth of brake pad is Increase in demand for safety, better performance
E-passport and E-visa Market Emerging Technological Growth, Demand and Business …
E-passport and E-visa Market research report focuses on the leading competitors and provides information such as the company overview, product portfolio, key developments, price, cost, value, volume, revenue, capacity, production, and contact information. Upstream raw materials and equipment and downstream demand analysis have also been carried out in this report. The report also analyses the current development trends and patterns, as well as the distribution and marketing channel. The key manufacturers

All 5 Releases

More Releases for Pharma

Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Clomifene Citrate Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Clomifene Citrate Market" across the global, regional and country level. The report provides 360° analysis of "Clomifene Citrate Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Clomifene Citrate industry, and estimates the future trend of Clomifene Citrate market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business